Neuraly – Page 2 – Boston Harbor Angels

21JulJuly 21, 2018

Johns Hopkins spinout Neuraly launches with $36M funding round

The Maryland biotech startup is developing new treatments for Parkinson's disease and Alzheimer’s disease. Read more >>

Portfolio NewsNeuraly

19JulJuly 19, 2018

Startup Neuraly Raises $36M to Bring Potential Disease-Modifying Treatments to Patients with Parkinson’s Disease

Today, Neuraly announced its launch to pioneer the development of disease-modifying agents for neurodegenerative disorders. Read more >>

Portfolio NewsNeuraly

26JunJune 26, 2018

The Power Couple of Parkinson’s Research

Neuraly has raised $35 million in support of its research and is preparing for clinical trials expected to begin later this year. Read more >>

Portfolio NewsNeuraly

28MarMarch 28, 2017

Boston Harbor Angels Bet on New Frontier in Neuroscience

Boston Harbor Angels has invested in two neuroscience startups targeting stroke, TBI and Parkinson's Disease, leading a $1.3M angel seed round in Astrocyte Pharmaceuticals and members investing in Neuraly. Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI,...

Organization News, Portfolio News, Press ReleaseAstrocyte Pharmaceuticals, Neuraly